The burgeoning landscape of medication for weight management and type 2 metabolic disorder is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant differences in their pharmacological profiles and clinical study results are emerging. Re… Read More

Arriving in the landscape of excess body fat management, retatrutide represents a unique method. Different from many available medications, retatrutide operates as a double agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) receptors. This simultaneous activation promotes severa… Read More